In addition, previous studies demonstrated that high KL-6 levels were associated with poor clinical outcomes in NSCLC patients who underwent surgery or received tyrosine kinase inhibitor treatment [40, 41]. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.